Allarity Therapeutics (ALLR) Non-Current Deferred Tax Liability (2020 - 2024)
Allarity Therapeutics' (ALLR) quarterly Non-Current Deferred Tax Liability came in at $432000.0 in Q2 2024, up 25.95% YoY from $343000.0 in Q3 2023, and little changed on a QoQ basis from $432000.0 in Q1 2024.
Allarity Therapeutics (ALLR) Non-Current Deferred Tax Liability (2020 - 2024) Analysis & Trends
Allarity Therapeutics (ALLR) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $432000.0 in Q2 2024.
- Quarterly Non-Current Deferred Tax Liability rose 25.95% year-over-year to $432000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $432000.0 (up 25.95% YoY) and the FY2023 annual result came in at $446000.0, up 27.79% from the prior year.
- Non-Current Deferred Tax Liability steadied at $432000.0 in Q2 2024, from $432000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.3 million in Q3 2021 to a low of $293000.0 in Q2 2021.
- A 5-year average of $809500.0 and a median of $439000.0 in 2023 frame the typical range for Non-Current Deferred Tax Liability.
- The widest YoY moves for Non-Current Deferred Tax Liability: up 123.89% in 2022, down 82.2% in 2022.
- Tracing ALLR's Non-Current Deferred Tax Liability over 5 years: stood at $2.1 million in 2020, then slipped by 8.15% to $2.0 million in 2021, then tumbled by 82.2% to $349000.0 in 2022, then increased by 27.79% to $446000.0 in 2023, then decreased by 3.14% to $432000.0 in 2024.
- The last three Non-Current Deferred Tax Liability figures came in at $432000.0 (Q2 2024), $432000.0 (Q1 2024), and $446000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Allarity Therapeutics | 22.75 Mn | 22.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 432,000.00 |
| Jun 30, 2024 | 432,000.00 |
| Mar 31, 2024 | 432,000.00 |
| Mar 31, 2024 | 432,000.00 |
| Dec 31, 2023 | 446,000.00 |
| Dec 31, 2023 | 446,000.00 |
| Sep 30, 2023 | 343,000.00 |
| Sep 30, 2023 | 343,000.00 |
| Jun 30, 2023 | 343,000.00 |
| Jun 30, 2023 | 343,000.00 |
| Mar 31, 2023 | 343,000.00 |
| Mar 31, 2023 | 343,000.00 |
| Dec 31, 2022 | 349,000.00 |
| Dec 31, 2022 | 349,000.00 |
| Sep 30, 2022 | 619,000.00 |
| Sep 30, 2022 | 619,000.00 |
| Jun 30, 2022 | 656,000.00 |
| Jun 30, 2022 | 656,000.00 |
| Mar 31, 2022 | 700,000.00 |
| Mar 31, 2022 | 700,000.00 |